News

The latest announcement comes after the previously granted ODD for polihexanide in acanthamoeba keratitis by the FDA and EMA.

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.

The company’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilize and reshape the cornea.

Dongkyun Lang, a biomedical engineering and optical sciences professor, is developing a way to diagnose and treat corneal ulcers that is eight times cheaper and 20 times faster than today's gold standard.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.

Kathryn A. Colby, MD, PhD, discusses Fuchs’ dystrophy symptoms and treatment options as well as the underlying concept of Descemet stripping only surgery and her role in pioneering this technique.

Luis Acaba-Berrocal, MD, of the Illinois Eye and Ear Infirmary in Chicago, worked with a group of colleagues to conduct a multicenter, retrospective, consecutive study of infants with ROP who had been treated with intravitreal anti-VEGF injections between 2008 and 2020 in light of the dearth of real-world data on the topic.

A gift from Bronwyn Bateman, MD, will establish the UCLA Bronwyn Bateman Center for Ocular Genetics at the Stein Eye Institute.

Russian bombs on Wednesday struck a hospital in Mariupol, Ukraine, damaging several buildings, including an ophthalmology department. Elsewhere, physicians are participating in relief efforts.

Investigators studying old flies have gained some new insight into retinal degeneration, seeking an understanding "of the molecular mechanisms that drive age-associated changes and the external and internal factors that influence them.”

Bennie H. Jeng, MD, a corneal specialist, will assume his new role at Penn in July, succeeding Joan O’Brien, who will assume a new role as the inaugural director of the Penn Medicine Center for Ophthalmic Genetics in Complex Diseases.

Trial recruitment is enabled by the Foundation Fighting Blindness' patient registry, My Retina Tracker Registry, which includes gene

Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.

The company this week is rolling out its Clareon family of IOLs, including Monofocal, PanOptix and Vivity options.

Goal-based retirement planning is different from longevity planning.

Ameet Goyal, MD, 58, recently pled guilty in the Southern District of New York to all charges for orchestrating a seven-year healthcare fraud scheme by falsely billing for millions of dollars of upcoded procedures, and also for fraudulently obtaining two government-guaranteed loans intended to help small businesses during the COVID-19 pandemic.

In advance of World Glaucoma Week March 6-12, a study of 3826 patients with glaucoma has found significantly higher odds of self-reported difficulty affording medication observed among non-Hispanic African American and Hispanic individuals compared with non-Hispanic White individuals.

The company notes that the system’s design includes a small footprint, enhanced ergonomics, superior imaging, dual-pulsed laser, and advanced astigmatism management tools.

Christina Y. Weng, MD, MBA, an associate professor of ophthalmology and surgical retina fellowship program director at Baylor College of Medicine in Houston, recently shared some standout therapies for macular degeneration.

New World Medical notes that the intuitively designed Streamline features ClickPulse technology that targets the eye’s conventional outflow pathway.

The companies note that the partnership will propel Ray Therapeutics’ lead optogenetics gene therapy to Phase 1-2 clinical trials.

The eye care nonprofit has continually harnessed the power of innovation to reach new heights in the fight against avoidable blindness.

The group is offering free sight-savings resources to employees and their employers.

This novel surgical system could dramatically improve outcomes for patients with glaucoma with its remarkable level of precision that is unachievable during standard glaucoma surgery.

According to the U.S. Department of Health and Human Services, nearly $19 billion in total aid has been distributed to providers since November.

Aleksandra Rachitskaya, MD, discusses how the treatment landscape for inherited retinal diseases has changed and her hope for the future.

The organization uses its Eyes on Capitol Hill program to educate lawmakers and their staff on a variety of vision health issues, including vision health inequities, the need for improved vision surveillance, the impact of community eye health programs, and disparities in access to affordable eyecare services.